Orionis Biosciences Appoints Dr. Giulio Draetta as Chief Strategy Officer

Amid strong pipeline growth, the biotech firm strengthens its leadership team.

Apr. 1, 2026 at 3:24pm

Got story updates? Submit your updates here. ›

Orionis Biosciences, a privately held, clinical-stage life sciences company, has appointed Dr. Giulio Draetta as its new Chief Strategy Officer. Draetta is a renowned scientist and biopharma leader with extensive expertise in medical sciences, drug discovery, clinical translation, and global partnerships.

Why it matters

The appointment of Dr. Draetta as Chief Strategy Officer comes as Orionis Biosciences experiences strong growth in its drug development pipeline. His expertise is expected to help guide the company's strategic direction and accelerate its progress in bringing new precision medicines to market.

The details

Orionis Biosciences is a clinical-stage life sciences company focused on discovering, designing, and developing precision medicines. The addition of Dr. Draetta to the leadership team is intended to strengthen the company's capabilities as it advances its drug pipeline.

  • Orionis Biosciences announced the appointment on April 1, 2026.

The players

Orionis Biosciences

A privately held, clinical-stage life sciences company focused on discovery, design and development of precision medicines.

Dr. Giulio Draetta

A renowned scientist and biopharma leader with extensive expertise in medical sciences, drug discovery, clinical translation, and global partnerships.

Got photos? Submit your photos here. ›

The takeaway

The appointment of Dr. Draetta as Chief Strategy Officer at Orionis Biosciences reflects the company's commitment to strengthening its leadership team and accelerating the development of its precision medicine pipeline.